Nature Search

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

In an ongoing adaptive-design trial exploring different combinations of neoadjuvant immunotherapies including the anti-PD-1 agent pembrolizumab, the anti-TIGIT agent vibostolimab and the oncolytic virus gebasaxturev, neoadjuvant pembrolizumab-based regimens elicited encouraging clinical responses in patients with resectable melanoma.

Reinhard Dummer
Caroline Robert
Georgina V. Long
ResearchOpen Access07 Jan 2025
Nature Medicine

Volume: 31, P: 144-151
Expression and regulation of Cyr61 in human breast cancer cell lines

Miaw-Sheue Tsai
Daphne F Bogart
Ruth Lupu
Research12 Feb 2002
Oncogene

Volume: 21, P: 964-973
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer

Miaw-Sheue Tsai
Lisa A Shamon-Taylor
Ruth Lupu
Research05 Feb 2003
Oncogene

Volume: 22, P: 761-768
A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity

Ella Atlas
Kozystof Bojanowski
Ruth Lupu
Research29 May 2003
Oncogene

Volume: 22, P: 3441-3451
A novel CYR61-triggered ‘CYR61-α_vβ₃ integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway

Javier A Menendez
Luciano Vellon
Ruth Lupu
Research13 Dec 2004
Oncogene

Volume: 24, P: 761-779
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

Javier A Menendez
Bharvi P Oza
Ruth Lupu
Research19 Apr 2004
Oncogene

Volume: 23, P: 4945-4958

Quick links

Search

Filter By:

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

Expression and regulation of Cyr61 in human breast cancer cell lines

Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer

A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity

A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway

Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

Search

Quick links

A novel CYR61-triggered ‘CYR61-α_vβ₃ integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway